The present invention pertains to certain 6-carboaryloxy-pyrazin-2-yl-carboaryl-amines of the following formula, and pharmaceutically acceptable salts thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., wherein Q is independently --N.dbd.; R.sup.P3 is independently a group of the formula -J.sup.1-L.sup.1-Z; -J.sup.1L.sup.1-Z is independently --NH--Z; Z is independently C.sub.6-14carboaryl and is independently unsubstituted or substituted; R.sup.P2 is independently --H; R.sup.P5 is independently a group of the formula --W--Y; W is independently --O--; Y is independently C.sub.6-14 carboaryl and is independently unsubstituted or substituted; and R.sup.P6 is independently --H. The present invention also pertains to pharmaceutical compositions comprising such compounds. ##STR00001##